Notice to an extraordinary general meeting of
The shareholders of
Notice of Attendance
A shareholder who would like to participate in the General Meeting shall:
(i) be entered in the register of shareholders maintained by
(ii) notify the Company of their intention to attend the General Meeting no later than than Monday
Notification of participation shall be sent by mail to
In order to be entitled to participate in the General Meeting, a shareholder who has registered their shares in the name of a nominee, in addition to announcing their intention to participate, must temporarily request that their shares be registered in their own name so the shareholder is entered into the register of shareholders by
Proxies
Shareholders represented by proxy shall issue a written and dated power of attorney. The power of attorney may not be older than one year unless indicated that it is valid for a longer period, not exceeding five years. If the proxy is issued by a legal person, a certified copy of the registration certificate or similar papers of authorisation are also required. Power of attorney, registration certificates and other authorisation documents must be available for the Meeting and, in order to facilitate entry to the Meeting, sent to the Company at the above address, no later than
Proposed agenda
- Election of Chairman of the Meeting
- Election of one person or two persons to certify the minutes
- Preparation and approval of the voting list
- Approval of the agenda
- Establishment of whether the Meeting has been duly convened
- Resolution on issue of new shares
- Closing of the Meeting
Proposals
Resolution on issue of new shares (item 6)
The shareholder
The new shares may, with deviation from the shareholders' preferential right, only be subscribed for by
Subscription must take place no later than
The purpose of the new issue and the reason for the deviation from the shareholders' preferential right is to enable the Company to settle outstanding loan amounts of a total of
The company's managing director is authorized to make minor formal adjustments to the issue resolution that may prove necessary in connection with registration of the new shares with the Swedish Companies Registration Office or
For a valid decision of the General Meeting according to the above proposal, it is required that the resolution be supported by shareholders who represent at least two thirds of both the votes cast and the shares represented at the General Meeting.
The shareholders' right to submit questions
The shareholders are reminded of their right, in accordance with Chapter 7 Section 32 of the Swedish Companies Act, to request information from the Board and the CEO at the Meeting.
Other information
As per
https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
The Board of Directors of the Company will issue a separate press release to be announced in connection with the announcement of this notice to convene the Extraordinary General Meeting. The press release will also be available at the Company's website, www.irras.com.
Documents
The complete proposal according to item 6 above, together with documents according to the Swedish Companies Act (2005:551) will be available at the Company's office at the address set out above and will be sent free of charge to shareholders who so request and provide their postal address or e-mail address. The documents will also be available at the Company's website, www.irras.com.
_____
The Board of Directors
This disclosure contains information that IRRAS is obliged to make public pursuant to the EU
Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication,
through the agency of the contact person, on
For more information, please contact:
President and Chief Executive Officer
ir@irras.com
About IRRAS
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in
IRRAS maintains its headquarters in
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
https://news.cision.com/irras/r/notice-to-an-extraordinary-general-meeting-of-irras-ab,c3837320
https://news.cision.com/irras/i/3837320-0-png,c3216795
(c) 2023 Cision. All rights reserved., source